Next Article in Journal
The Role of Microfluidics for Organ on Chip Simulations
Next Article in Special Issue
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy
Previous Article in Journal
Bio-Inspired Multi-Functional Drug Transport Design Concept and Simulations
Previous Article in Special Issue
Use of Recombinant Mucin Glycoprotein to Assess the Interaction of the Gastric Pathogen Helicobacter pylori with the Secreted Human Mucin MUC5AC
Open AccessArticle

Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans

Laboratory of Biochemistry, Department of Life Sciences and Technology, Beuth University of Applied Sciences Berlin, Seestrasse 64, 13347 Berlin, Germany
Department of Life Science Engineering, HTW Berlin University of Applied Sciences, Wilhelminenhofstraße 75a, 12459 Berlin, Germany
Molecular Biotechnology and Functional Genomics, Technical University of Applied Sciences Wildau, Hochschulring 1, 15745 Wildau, Germany
Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Medical University Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
ProBioGen AG, Goethestrasse 54, 13086 Berlin, Germany
Author to whom correspondence should be addressed.
Academic Editor: Anthony Guiseppi-Elie
Bioengineering 2017, 4(2), 38;
Received: 31 March 2017 / Revised: 22 April 2017 / Accepted: 24 April 2017 / Published: 28 April 2017
(This article belongs to the Special Issue Recombinant Glycoproteins)
Xylose is a general component of O-glycans in mammals. Core-xylosylation of N-glycans is only found in plants and helminth. Consequently, xylosylated N-glycans cause immunological response in humans. We have used the F-protein of the human respiratory syncytial virus (RSV), one of the main causes of respiratory tract infection in infants and elderly, as a model protein for vaccination. The RSV-F protein was expressed in CHO-DG44 cells, which were further modified by co-expression of β1,2-xylosyltransferase from Nicotiana tabacum. Xylosylation of RSV-F N-glycans was shown by monosaccharide analysis and MALDI-TOF mass spectrometry. In immunogenic studies with a human artificial lymph node model, the engineered RSV-F protein revealed improved vaccination efficacy. View Full-Text
Keywords: CHO; glycoengineering; respiratory syncytial virus; vaccine; xylose CHO; glycoengineering; respiratory syncytial virus; vaccine; xylose
Show Figures

Figure 1

MDPI and ACS Style

Sandig, G.; Von Horsten, H.H.; Radke, L.; Blanchard, V.; Frohme, M.; Giese, C.; Sandig, V.; Hinderlich, S. Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans. Bioengineering 2017, 4, 38.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop